Opinion
Video
APOC3 Inhibitors
Author(s):
Key Takeaways
- Delayed FCS diagnosis can lead to exacerbated cardiovascular and metabolic consequences, increasing atherosclerosis and cardiovascular disease risk.
- Persistent hypertriglyceridemia from untreated FCS may result in chronic pancreatitis, diabetes, and liver disease.
Panelists discuss important novel therapies emerging for familial chylomicronemia syndrome (FCS), focusing on APOC3 inhibitors, including small interfering RNA (siRNA) and antisense oligonucleotides (ASO), and their potential to address the underlying lipid metabolism dysfunction in patients with FCS.
Video content above is prompted by the following:
Can you review important novel therapies for FCS that are APOC3 inhibitors (siRNA and ASO) that have recently emerged?
Related Videos
Related Content
